Research programme: anticancer monoclonal antibodies - CFD Therapeutics

Drug Profile

Research programme: anticancer monoclonal antibodies - CFD Therapeutics

Alternative Names: DD-0110; DD-0115; DD-0232V3; DD-C106; DD-C237V1; DD-C242; DD-P104; DD-P115

Latest Information Update: 10 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator diaDexus
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 24 Jul 2007 MAbs against targets DD-0110 and DD-0115 are being tested in mouse xenograft models
  • 04 Apr 2006 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top